Patients 
Introduction
Several factors are known to influence survival of women with breast cancer,' but little is known of the prognostic influence of different blood groups. In a series of 1323 radical mastectomies for cancer carried out from 1940 to 1965 Donegan associated 10 year survival with various constitutional, clinical, and pathological factors, and analysis of the blood groups of 986 patients showed that a good survival was associated with blood group AB (10 year relative survival 66-20' ) and a poor survival with blood group B (10 year relative survival 27o ). 2 We present a similar sized series and compare the results. 
Discussion
If blood group is associated with survival from other diseases6 there would be some bias in the population towards older women. At the time of analysis, however, the only suitable information available on blood groups in the population was that from the Blood Transfusion Service, and a non-significant result was obtained when distributions were compared. In addition, the analysis was concerned with prognosis, not the risk of development of breast cancer.
In contrast with the results obtained in this series Donegan found a "good" relative survival in patients with blood group AB, although figures for other blood groups were comparable.2 The exact reason for this difference is not clear as he did not discuss his findings in detail. We can only postulate possible causes such as differences in the distribution of blood groups in the population studied or different methods of selecting cases for the study.
By applying the log rank method and Cox's model we found that the type of blood group retained its significance and could be regarded as an independent factor of prognostic value, not explained by the presence of known clinical or pathological risk factors. We therefore believe that blood group should be considered in addition to these risk factors when a patient's prognosis is assessed. Case report A 13 year old boy presented with fluid retention. Biopsy showed cirrhosis of the liver. He was treated symptomatically. Three years later his younger sister died suddenly of liver failure; a genetic illness was suspected. A year later he developed dysarthria, and examination showed hepatosplenomegaly, gynaecomastia, and Kayser-Fleischer rings. His serum copper concentration was 4-1 HtmollI (26 sLg/I00 ml) and urine copper excretion over 3 1 jimol/24 h (200 ,g/24 h). Penicillamine was started, and symptoms of the hepatic and the neurological disease rapidly cleared; after two years, however, he developed severe systemic lupus and a nephrotic syndrome. Penicillamine was stopped and prednisolone 5 mg daily started.
The systemic lupus did not respond, and after two months he was referred This treatment was continued, plus prednisolone 10 mg daily, from February 1982, and, apart from heavy proteinuria, his health remained good. His blood and urine copper concentrations fell, though basal urine copper excretion was still higher than when penicillamine was stopped.
Comment
Although this particular water soluble analogue of dimercaprol has been used in Eastern Bloc countries for some time, it has not been available in western Europe, so little is known of its toxicity. One problem with the parent compound, dimercaprol, was the
